Sézary syndrome: old enigmas, new targets
- PMID: 26972187
- DOI: 10.1111/ddg.12900
Sézary syndrome: old enigmas, new targets
Abstract
Sézary syndrome, the leukemic variant of cutaneous T-cell lymphoma, is still an enigmatic disease with a fatal prognosis. Recent research, however, has identified a multitude of dysregulated molecular pathways that contribute to malignant transformation and therapy resistance of Sézary cells (SC). With respect to T-cell development, SC either represent naive T cells, T effector memory or T central memory cells. Functionally, SC may differentiate into Th2, Treg, or even Th17 cells. Despite their plasticity, SC express characteristic diagnostic marker proteins including CD158k, CD164, FcRL3, and PD-1 as well as skin-homing receptors such as CLA and CCR4. Already tested in (pre)clinical trials, CD158k, PD-1, CTLA-4, and CCR4 also represent promising therapeutic targets. Molecular alterations in SC include transcription factors such as STAT3, 4, and 5, as well as TWIST1 and TOX. TWIST1 induces expression of DNM3os containing the miR-199a2/214 cluster, a key hub controlling multiple cancer networks. In addition, activation of NFκB and the MAPK pathway as well as altered TCR signaling cause apoptosis resistance. Recently, whole genome and exome sequencing has revealed somatic copy number variations as predominant mutations in SC, primarily affecting apoptosis, NFκB signaling, DNA integrity, and T-cell activation. In order to facilitate development of novel therapies, improved in vivo models, which better reflect the pathogenesis and clinical course of Sézary syndrome, are currently being generated.
© 2016 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
Comment in
-
Das Sézary Syndrom--Neuste molekulare und immunologische Erkenntnisse.J Dtsch Dermatol Ges. 2016 Mar;14(3):225-7. doi: 10.1111/ddg.12978. J Dtsch Dermatol Ges. 2016. PMID: 26972184 German. No abstract available.
Similar articles
-
CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20. Arch Dermatol Res. 2017. PMID: 27766406 Free PMC article.
-
Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.Cell Death Dis. 2018 Dec 5;9(12):1178. doi: 10.1038/s41419-018-1212-7. Cell Death Dis. 2018. PMID: 30518749 Free PMC article.
-
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.Nat Genet. 2015 Dec;47(12):1465-70. doi: 10.1038/ng.3442. Epub 2015 Nov 9. Nat Genet. 2015. PMID: 26551667 Free PMC article.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
-
Tumor microenvironment in mycosis fungoides and Sézary syndrome.Curr Opin Oncol. 2016 Jan;28(1):88-96. doi: 10.1097/CCO.0000000000000243. Curr Opin Oncol. 2016. PMID: 26632770 Review.
Cited by
-
Aberrant microRNA expression in tumor mycosis fungoides.Tumour Biol. 2016 Nov;37(11):14667-14675. doi: 10.1007/s13277-016-5325-2. Epub 2016 Sep 13. Tumour Biol. 2016. PMID: 27623940
-
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021.J Dtsch Dermatol Ges. 2022 Apr;20(4):537-554. doi: 10.1111/ddg.14706. J Dtsch Dermatol Ges. 2022. PMID: 35446497 Free PMC article. No abstract available.
-
Verlust der Fingerabdrücke bei zwei Patienten mit Sézary-Syndrom: klinische und dermatoskopische Beurteilung.J Dtsch Dermatol Ges. 2020 Oct;18(10):1184-1185. doi: 10.1111/ddg.14302_g. J Dtsch Dermatol Ges. 2020. PMID: 33112065 Free PMC article. German. No abstract available.
-
Types of T-cell lymphoma-a cytogenetic perspective.Ann Med Surg (Lond). 2022 Nov 9;84:104844. doi: 10.1016/j.amsu.2022.104844. eCollection 2022 Dec. Ann Med Surg (Lond). 2022. PMID: 36536747 Free PMC article.
-
Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma.Leukemia. 2024 Nov 23. doi: 10.1038/s41375-024-02479-1. Online ahead of print. Leukemia. 2024. PMID: 39580583
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous